Evaluation of treatment and switching patterns for Dry Eye Disease medications using linked EHR and Claims data Authors: Michael Mbagwu^{1,2}, Andrew LaPrise¹, Jennifer Toth¹, Eric Stone¹, Joel Fain³, David J. Harrison³

Affiliations: ¹Verana Health, San Francisco, California, ²Stanford University, School of Medicine, Department of Ophthalmology Palo Alto, CA ³ Bausch + Lomb, Bridgewater, New Jersey

BACKGROUND

Dry Eye Disease (DED) is a multifactorial chronic condition of the tear film and ocular surface impacting the quality of life and visual comfort for millions of individuals. Current DED medications require consistent use for at least 3 months or more for symptomatic relief. Previous reports suggest a high discontinuation rate, implying suboptimal real-world efficacy for long term DED management.

Among the pharmacological interventions available for DED management, three prescription treatments are commonly used in clinical practice:

- Restasis® (cyclosporine ophthalmic emulsion 0.05%
- Xiidra® (lifitegrast ophthalmic solution 5%)

METHODS

- This retrospective cohort study used the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) linked with Komodo Health claims data between January 2017 – June 2022.
- Study examined treatment patterns, switching and discontinuation for commonly prescribed DED medications viz. Restasis[®], Xiidra[®] and CequaTM.
- The first pharmacy claim for a medication of interest between January 2018 and June 2021 defined the index date.
- Treatment switch was defined as the start of a new DED medication type within 60 days after the last claim for the index DED medication plus its days' supply.
- Discontinuation of the index medication was defined as a gap of ≥ 60 days between the end of the days' supply and next refill of the index medication or a treatment switch prior to discontinuing the index medication.

	- 360 days (Pre-index period)	360 days (Post-index period)	
January 1, 2017	Index	Date	June 30, 2022
	۲ Study Dat	a Period	

Figure 1. Study Design

SULTS	
east one pharmacy claim in the study period for Restasis, Xiidra or Cequa between January 1, 2018 – Jun	e 30, 202
N = 835,235 (100%)	
At least 18 years old at first pharmacy claim for Restasis, Xiidra or Cequa in the study period	
N = 828,183 (99.2%)	
At least 360 days of continuous enrollment in closed claims before and after the index date	
N = 238,029 (28.5%)	
Diagnosis code for Dry Eye Disease (DED) in the 360 days prior to the index date in the IRIS Registry	
N = 105,804 (12.7%)	
Exclude patients with missing age or sex information	
N = 105,793 (12.7%)	
xclude patients with claim for Restasis, Xiidra, Cequa, Tyrvaya, or Lacrisert in the 360 days prior to the inde	ex date
N = 79,979 (9.6%)	
Exclude patients with days' supply greater than 100 days	
N = 79,848 (9.6%)	
Exclude patients with more than one index DED medication	
N = 79,719 (9.5%)	
Exclude patients with documentation of punctal plugs or punctal cautery in the 360 days prior to index	date
N = 73,356 (8.8%)	

Figure 2. Study Attrition Diagram

Results

- On average, patients prescribed Restasis were about 5 years older than those prescribed other DED medications.
- The majority of patients across all three treatments were female (~80%)
- The majority of patients across all three treatments had an ICD-10 code suggesting aqueous deficient DED
- Table 1. Baseline Characteristics


	Restasis N=47,859 (65.2%)	Xlidra N=23,706 (32.3%)	Cequa N=1,791 (2.4%)			
Age						
Age (years) Mean ± SD	61.7 ± 13.7	56.6 ± 13.1	56.7 ± 13.6			
Sex						
Female	80.9%	80.3%	79.7%			
Male	19.1%	19.7%	20.3%			
Race						
White or Caucasian	61.2%	64.1%	64.9%			
Black or African American	7.0%	5.7%	5.2%			
Asian	5.4%	4.7%	4.7%			
Other races	3.2%	2.5%	1.6%			
Unknown	23.2%	22.9%	23.6%			
Ethnicity						
Hispanic	11.8%	9.2%	7.4%			
Non-Hispanic	59.0%	60.1%	59.2%			
Unknown	29.2%	30.7%	33.4%			
Insurance / Payer Type						
Medicare	17.0%	10.5%	10.1%			
Medicare Advantage	13.3%	16.9%	8.0%			
Medicaid	7.0%	7.0%	3.6%			
Commercial	47.8%	60.7%	64.3%			
Other/Unknown	15.0%	14.9%	14.1%			
Mechanism of DED						
Evaporative	0.4%	0.6%	1.1%			
Evaporative Mix	4.2%	4.7%	8.9%			
Aqueous Deficient	85.9%	84.8%	77.9%			
Multiple	7.0%	7.8%	9.0%			
Other	2.4%	2.1%	3.0%			

RESULTS

 $\overline{}$

• Mean time on therapy was similar for Restasis [95.8 days(SD 76.9)] and Xiidra [90.5 days (SD78.8)]and somewhat lower for Cequa [77.5 days(SD66.8)].

• For all three medications over half of patients only filled a single script.



RESULTS

• Switching was relatively uncommon; only 2.8% of Restasis, 6.5% of Xiidra, and 7.8% of Cequa patients switched to a different DED medication during the study period.